PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
Authors
Keywords
PRAME, PReferentially Antigen expressed in Melanoma, Triple negative breast cancer, Migration, Invasion, Epithelial-to-mesenchymal transition
Journal
Journal of Translational Medicine
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-03
DOI
10.1186/s12967-018-1757-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway
- (2018) Hanzhang Zhu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
- (2018) Zhixian Liu et al. Translational Oncology
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
- (2018) Remy Thomas et al. Frontiers in Immunology
- Recent Advances in the Treatment of Breast Cancer
- (2018) Christy W. S. Tong et al. Frontiers in Oncology
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells
- (2017) Cornelia Siebenkäs et al. PLoS One
- PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma
- (2017) Gülçin Gezgin et al. JAMA Ophthalmology
- PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
- (2016) M. G. Field et al. CLINICAL CANCER RESEARCH
- PRAME is critical for breast cancer growth and metastasis
- (2016) Zhengwang Sun et al. GENE
- The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients
- (2016) Sumitra Thongprasert et al. LUNG CANCER
- Wnt signaling in cancer
- (2016) T Zhan et al. ONCOGENE
- Preferentially Expressed Antigen of Melanoma Prevents Lung Cancer Metastasis
- (2016) Quan Huang et al. PLoS One
- Induction of WNT11 by hypoxia and hypoxia-inducible factor-1α regulates cell proliferation, migration and invasion
- (2016) Hiroyuki Mori et al. Scientific Reports
- Bone Morphogenetic Protein-7 Inhibits EMT-Associated Genes in Breast Cancer
- (2015) Xuexiang Ying et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Diagnostic marker signature for esophageal cancer from transcriptome analysis
- (2015) Ute Warnecke-Eberz et al. TUMOR BIOLOGY
- Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells
- (2015) Christopher Dravis et al. Cell Reports
- Molecular mechanisms of epithelial–mesenchymal transition
- (2014) Samy Lamouille et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The Notch ligand Jagged1 as a target for anti-tumor therapy
- (2014) Demin Li Frontiers in Oncology
- Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma?
- (2013) Miroslaw J Szczepanski et al. Biomarkers in Medicine
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
- (2013) H. Masuda et al. CLINICAL CANCER RESEARCH
- PRAME Gene Expression in Childhood Acute Lymphoblastic Leukemia: Impact on Prognosis
- (2013) Ca Abdelmalak et al. Clinical Laboratory
- PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy
- (2013) D. D. De Carvalho et al. CURRENT MOLECULAR MEDICINE
- Knock-Down of PRAME Increases Retinoic Acid Signaling and Cytotoxic Drug Sensitivity of Hodgkin Lymphoma Cells
- (2013) Stefanie Kewitz et al. PLoS One
- Expression and prognostic relevance of PRAME in primary osteosarcoma
- (2012) Pingxian Tan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas
- (2012) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Global estimates of cancer prevalence for 27 sites in the adult population in 2008
- (2012) Freddie Bray et al. INTERNATIONAL JOURNAL OF CANCER
- Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: Effect of 5-AZA treatment
- (2012) S. Gutierrez-Cosío et al. LEUKEMIA RESEARCH
- PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions
- (2012) Miroslaw J. Szczepanski et al. ORAL ONCOLOGY
- Epithelial-Mesenchymal Transition: General Principles and Pathological Relevance with Special Emphasis on the Role of Matrix Metalloproteinases
- (2012) P. Nistico et al. Cold Spring Harbor Perspectives in Biology
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells
- (2011) Norina Tanaka et al. LEUKEMIA RESEARCH
- -catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness
- (2011) E. Sanchez-Tillo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia
- (2010) Frances Wadelin et al. Molecular Cancer
- Aberrant hypomethylation of the cancer–testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia
- (2008) Christina A. Ortmann et al. ANNALS OF HEMATOLOGY
- PRAME expression and clinical outcome of breast cancer
- (2008) M T Epping et al. BRITISH JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started